Skip to content

Survey of Pregabalin augmentation in patients with chronic post traumatic stress disorder

Survey of Pregabalin augmentation in patients with chronic post traumatic stress disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201302145280N12
Enrollment
38
Registered
2013-08-30
Start date
2012-09-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic Post-traumatic stress disorder( PTSD). Post-traumatic stress disorder

Interventions

Intervention 1: The case group received SSRI( Serteraline 50-200 mg or citalopram 20-40 mg) daily for 6 weeks. received Pregabalin (75 mg/day for the first week then 75 mg twice daily for the second w
Treatment - Drugs
The case group received SSRI( Serteraline 50-200 mg or citalopram 20-40 mg) daily for 6 weeks. received Pregabalin (75 mg/day for the first week then 75 mg twice daily for the second week and continue
control group received placebo and routine treatment daily for 6 weeks.

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
35 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnose with PTSD based on DSM-IV-TR criteria, age between 30 and 65 years, had no significant cognitive disorder and no history of drug abuse except for nicotine. Exclusion criteria: were unwillingness of patients to continue the trial; active medical disease, other diseases in axis one or two except for PTSD and sensitivity to Pregabalin.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Post traumatic stress disorder. Timepoint: 0, 2, 4 and 6th weeks. Method of measurement: PCL test.

Secondary

MeasureTime frame
Quality of life. Timepoint: 0, 2, 4 and 6th weeks. Method of measurement: Spitzer Quality of Life index( SQL).;Depression. Timepoint: 0, 2, 4 and 6th weeks. Method of measurement: Hamilton Depression Rating Scale.;Anxiety. Timepoint: 0, 2, 4 and 6th weeks. Method of measurement: Hamilton Anxiety Rating Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mahdi Baniasadi

Mashhad University of Medical Sciences

mehdi.baniasadi@yahoo.com+98 51 1711 2721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026